ONGLYZA
Total Payments
$5.4M
Transactions
2,091
Doctors
632
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3,908 | 160 | 114 |
| 2023 | $2,753 | 133 | 76 |
| 2022 | $511,140 | 132 | 63 |
| 2021 | $550,814 | 196 | 81 |
| 2020 | $442,533 | 121 | 41 |
| 2019 | $669,851 | 180 | 59 |
| 2018 | $1.3M | 416 | 186 |
| 2017 | $1.9M | 753 | 279 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 523 | 96.3% |
| Consulting Fee | $150,145 | 37 | 2.8% |
| Food and Beverage | $41,594 | 1,479 | 0.8% |
| Travel and Lodging | $10,622 | 50 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $939.75 | 2 | 0.0% |
Payments by Type
Research
$5.2M
523 transactions
General
$203,301
1,568 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 26 Week Multicenter Randomized Placebo Controlled Double Blind Parallel Group Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age | AstraZeneca UK Limited | $1.1M | 1 |
| CV181 358 PRESERVATION OF BETA CELL FUNCTION IN PREDIABETES IGT AND IFG | AstraZeneca Pharmaceuticals LP | $826,707 | 0 |
| A 24 Week International Open Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy | E.R. Squibb & Sons, L.L.C. | $692,780 | 0 |
| SAVOR. Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes | AstraZeneca Pharmaceuticals LP | $669,821 | 0 |
| A 24 Week Multicenter Randomized Double blind Parallel Group Placebocontrolled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure | AstraZeneca Pharmaceuticals LP | $489,096 | 0 |
| A 24 Week Multicenter Randomized Double blind Parallel Group Placebocontrolled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure | AstraZeneca AB | $344,854 | 0 |
| A 26 week International Multicenter Randomized Double Blind Active Controlled Parallel Group Phase 3bTrial With a Blinded 26 week Long Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co administered With Dapagliflozin in Co | E.R. Squibb & Sons, L.L.C. | $270,887 | 0 |
| Saxa Dapa vs Insulin | E.R. Squibb & Sons, L.L.C. | $178,267 | 0 |
| A 24 Week International Multi center Randomized Parallel group Double blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adults Subjects With Type 2 Diabetes Who Have Inadequate Glycemic C | E.R. Squibb & Sons, L.L.C. | $172,745 | 4 |
| Effect of Saxagliptin on adipose tissue inflammation. | AstraZeneca Pharmaceuticals LP | $146,379 | 0 |
| Effects of Saxagliptin on Adipos Tissue Inflammation in Humans | AstraZeneca Pharmaceuticals LP | $141,379 | 0 |
| A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin 1500 mg in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone | E.R. Squibb & Sons, L.L.C. | $98,048 | 0 |
| A 52 week International Multicenter Randomized Double Blind Active Controlled Parallel Group Phase 3bTrial With a Blinded 104 week Long Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co administered With Dapagliflozin in C | E.R. Squibb & Sons, L.L.C. | $56,294 | 0 |
| Saxa Dapa vs Glimepiride | E.R. Squibb & Sons, L.L.C. | $31,199 | 0 |
| A 24 Week Multicenter Randomized Double blind Parallel Group Placebocontrolled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure | AstraZeneca UK Limited | $16,234 | 0 |
| Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patients | AstraZeneca Pharmaceuticals LP | $13,250 | 0 |
| Effect of Saxagliptin (DPP-4) Inhibitor on Endothelial Progenitor (EPCs) as a cellular biomarker for evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients | AstraZeneca Pharmaceuticals LP | $5,000 | 0 |
| A 26 Week Multicenter Randomized Placebo Controlled Double Blind Parallel Group Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age | AstraZeneca Pharmaceuticals LP | $3,500 | 0 |
| A 26 week International Multicenter Randomized Double Blind Active Controlled Parallel Group Phase 3bTrial With a Blinded 26 week Long Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co administered With Dapagliflozin in Combinati | E.R. Squibb & Sons, L.L.C. | $750.00 | 0 |
| A 52 week International Multicenter Randomized Double Blind Active Controlled Parallel Group Phase 3bTrial With a Blinded 104 week Long Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co administered With Dapagliflozin in Combinat | E.R. Squibb & Sons, L.L.C. | $701.33 | 0 |
Top Doctors Receiving Payments for ONGLYZA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Family Medicine | Guayanilla, PR | $212.38 | 10 |
| , M.D: | Internal Medicine | Mayaguez, PR | $211.59 | 12 |
| , M.D | Endocrinology, Diabetes & Metabolism | San German, PR | $208.42 | 9 |
| , M.D | Internal Medicine | Yauco, PR | $199.15 | 10 |
| , M.D | Specialist | Guaynabo, PR | $191.33 | 10 |
| Edgar Moreno Rodriguez | Internal Medicine | San German, PR | $191.22 | 10 |
| , MD | Endocrinology, Diabetes & Metabolism | Merrillville, IN | $181.43 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Wheaton, IL | $181.43 | 2 |
| , M.D | Pediatrics | Tinley Park, IL | $181.43 | 2 |
| , M.D | Internal Medicine | Caguas, PR | $178.04 | 10 |
| , M.D | Family Medicine | San Juan, PR | $176.40 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Sabana Seca, PR | $168.76 | 9 |
| , M.D | General Practice | Sabana Grande, PR | $160.21 | 6 |
| , M.D | Endocrinology, Diabetes & Metabolism | Lombard, IL | $160.08 | 1 |
| , M.D | General Practice | San Sebastian, PR | $158.16 | 7 |
| , M.D | Endocrinology, Diabetes & Metabolism | Kalamazoo, MI | $157.10 | 2 |
| , MD | General Practice | Aguadilla, PR | $152.02 | 7 |
| , MD | Endocrinology, Diabetes & Metabolism | San German, PR | $145.86 | 7 |
| , M.D | Nuclear Medicine | Blue Ash, OH | $143.93 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Greensburg, PA | $142.35 | 1 |
| , M.D | Gastroenterology | Liberty Lake, WA | $142.35 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Rochester, NH | $142.35 | 1 |
| , M D | Endocrinology, Diabetes & Metabolism | Beachwood, OH | $142.35 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Augusta, GA | $142.35 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Jasper, GA | $142.35 | 1 |
Ad
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $2.4M
- E.R. Squibb & Sons, L.L.C. $1.5M
- AstraZeneca UK Limited $1.2M
- AstraZeneca AB $362,359
Product Information
- Type Drug
- Total Payments $5.4M
- Total Doctors 632
- Transactions 2,091
About ONGLYZA
ONGLYZA is a drug associated with $5.4M in payments to 632 healthcare providers, recorded across 2,091 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2017 to 2024. In 2024, $3,908 was paid across 160 transactions to 114 doctors.
The most common payment nature for ONGLYZA is "Unspecified" ($5.2M, 96.3% of total).
ONGLYZA is associated with 20 research studies, including "A 26 Week Multicenter Randomized Placebo Controlled Double Blind Parallel Group Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age" ($1.1M).